John W. Hanrahan - Search Results

Year	Number of Results
2002	2
2003	2
2004	3
2005	2
2006	4
2007	4
2008	6
2009	3
2010	2
2011	3
2012	7
2013	5
2014	3
2015	6
2016	6
2017	6
2018	6
2019	9
2020	5
2021	6
2022	6
2023	2
2024	2

1

Corrector combination therapies for F508del-CFTR.

Hanrahan JW, Matthes E, Carlile G, Thomas DY. Hanrahan JW, et al. Curr Opin Pharmacol. 2017 Jun;34:105-111. doi: 10.1016/j.coph.2017.09.016. Epub 2017 Nov 5. Curr Opin Pharmacol. 2017. PMID: 29080476 Review.

2

Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis.

Turner MJ, Abbott-Banner K, Thomas DY, Hanrahan JW. Turner MJ, et al. Among authors: hanrahan jw. Pharmacol Ther. 2021 Aug;224:107826. doi: 10.1016/j.pharmthera.2021.107826. Epub 2021 Mar 1. Pharmacol Ther. 2021. PMID: 33662448 Review.

3

Ionocyte-Specific Regulation of Cystic Fibrosis Transmembrane Conductance Regulator.

Sato Y, Kim D, Turner MJ, Luo Y, Zaidi SSZ, Thomas DY, Hanrahan JW. Sato Y, et al. Among authors: hanrahan jw. Am J Respir Cell Mol Biol. 2023 Sep;69(3):281-294. doi: 10.1165/rcmb.2022-0241OC. Am J Respir Cell Mol Biol. 2023. PMID: 36952679

4

Chronic obstructive pulmonary disease and the modulation of CFTR by acute exposure to cigarette smoke.

Hanrahan JW, Abu-Arish A, Wong FH, Turner MJ, Carlile GW, Thomas DY, Cantin AM. Hanrahan JW, et al. Am J Physiol Cell Physiol. 2022 Nov 1;323(5):C1374-C1392. doi: 10.1152/ajpcell.00356.2022. Epub 2022 Sep 19. Am J Physiol Cell Physiol. 2022. PMID: 36121129 Free article. Review.

5

CRISPR/Cas9 bioluminescence-based assay for monitoring CFTR trafficking to the plasma membrane.

Ondra M, Lenart L, Centorame A, Dumut DC, He A, Zaidi SSZ, Hanrahan JW, De Sanctis JB, Radzioch D, Hajduch M. Ondra M, et al. Among authors: hanrahan jw. Life Sci Alliance. 2023 Nov 2;7(1):e202302045. doi: 10.26508/lsa.202302045. Print 2024 Jan. Life Sci Alliance. 2023. PMID: 37918963 Free PMC article.

6

mRNA Delivery: Challenges and Advances through Polymeric Soft Nanoparticles.

Yousefi Adlsadabad S, Hanrahan JW, Kakkar A. Yousefi Adlsadabad S, et al. Among authors: hanrahan jw. Int J Mol Sci. 2024 Feb 1;25(3):1739. doi: 10.3390/ijms25031739. Int J Mol Sci. 2024. PMID: 38339015 Free PMC article. Review.

7

Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.

Hanrahan JW, Sato Y, Carlile GW, Jansen G, Young JC, Thomas DY. Hanrahan JW, et al. Expert Opin Ther Targets. 2019 Aug;23(8):711-724. doi: 10.1080/14728222.2019.1628948. Epub 2019 Jun 9. Expert Opin Ther Targets. 2019. PMID: 31169041 Review.

8

Investigating membrane protein dynamics in living cells.

Bates IR, Wiseman PW, Hanrahan JW. Bates IR, et al. Among authors: hanrahan jw. Biochem Cell Biol. 2006 Dec;84(6):825-31. doi: 10.1139/o06-189. Biochem Cell Biol. 2006. PMID: 17215870 Review.

9

F508del-CFTR is not corrected by thymosin α1.

Matthes E, Hanrahan JW, Cantin AM. Matthes E, et al. Among authors: hanrahan jw. Nat Med. 2018 Jul;24(7):890-891. doi: 10.1038/s41591-018-0079-6. Nat Med. 2018. PMID: 29942095 No abstract available.

10

Novel pharmacological strategies to treat cystic fibrosis.

Hanrahan JW, Sampson HM, Thomas DY. Hanrahan JW, et al. Trends Pharmacol Sci. 2013 Feb;34(2):119-25. doi: 10.1016/j.tips.2012.11.006. Trends Pharmacol Sci. 2013. PMID: 23380248 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

88 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year